Analyze Diet
Journal of veterinary internal medicine2024; 38(2); 1207-1213; doi: 10.1111/jvim.16988

Measurement of 8-hydroxy-2′-deoxyguanosine in serum and cerebrospinal fluid of horses with neuroaxonal degeneration and other causes of proprioceptive ataxia.

Abstract: Eight-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker of oxidative damage evaluated in human neurodegenerative disease, has potential to correlate with postmortem diagnosis of neuroaxonal dystrophy/degenerative myeloencephalopathy (NAD/DM) in horses. Objective: We hypothesized that 8-OHdG will be higher in CSF and serum from NAD/DM horses compared with horses with other neurologic diseases (CVSM, EPM) and a control group of neurologically normal horses. We also hypothesized that 8-OHdG will be higher in CSF compared with serum from NAD/DM horses. Methods: Fifty client-owned horses with postmortem diagnoses: 20 NAD/DM, 10 CVSM, 10 EPM, and 10 control horses. Serum and CSF samples were obtained between November 2010 and March 2022. Methods: Case-control study using biobanked samples was performed and commercial competitive ELISA kit (Highly Sensitive 8-OHdG Check ELISA) utilized. Concentration of 8-OHdG was quantitated in both CSF and serum and compared between groups. Results: No correlation was established between the measures of 8-OHdG in serum and CSF and group. CSF median [8-OHdG] for NAD/DM was 169.9 pg/mL (IQR : 67.18-210.6), CVSM 157.1 pg/mL (IQR : 132.1-229.1), EPM 131.4 pg/mL (IQR : 102.1-193.2), and control 149.8 pg/mL (IQR : 113.3-196.4). Serum median [8-OHdG] for NAD/DM was 130 pg/mL (IQR : 51.73-157.2), CVSM 125.8 pg/mL (IQR : 62.8-170.8), EPM 120.6 pg/mL (IQR : 87.23-229.7), and control 157.6 pg/mL (IQR : 97.15-245.6). Poisson regression analysis showed no difference established once confounding variables were considered. Conclusions: Eight-OHdG did not aid in antemortem diagnosis of NAD/DM in this cohort of horses. At the time of diagnosis horses with NAD/DM do not have ongoing oxidative stress.
Publication Date: 2024-01-11 PubMed ID: 38205913PubMed Central: PMC10937501DOI: 10.1111/jvim.16988Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Cite This Article

APA
Palmisano M, Kulp J, Bender S, Stefanovski D, Robinson M, Johnson A. (2024). Measurement of 8-hydroxy-2′-deoxyguanosine in serum and cerebrospinal fluid of horses with neuroaxonal degeneration and other causes of proprioceptive ataxia. J Vet Intern Med, 38(2), 1207-1213. https://doi.org/10.1111/jvim.16988

Publication

ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 38
Issue: 2
Pages: 1207-1213

Researcher Affiliations

Palmisano, Megan
  • Department of Clinical Studies, New Bolton Center, University of Pennsylvania School of Veterinary Medicine, Kennett Square, Pennsylvania, USA.
Kulp, Jeaneen
  • Department of Clinical Studies, New Bolton Center, University of Pennsylvania School of Veterinary Medicine, Kennett Square, Pennsylvania, USA.
Bender, Susan
  • Department of Pathobiology, New Bolton Center, University of Pennsylvania School of Veterinary Medicine, Kennett Square, Pennsylvania, USA.
Stefanovski, Darko
  • Department of Clinical Studies, New Bolton Center, University of Pennsylvania School of Veterinary Medicine, Kennett Square, Pennsylvania, USA.
Robinson, Mary
  • Department of Clinical Studies, New Bolton Center, University of Pennsylvania School of Veterinary Medicine, Kennett Square, Pennsylvania, USA.
Johnson, Amy
  • Department of Clinical Studies, New Bolton Center, University of Pennsylvania School of Veterinary Medicine, Kennett Square, Pennsylvania, USA.

MeSH Terms

  • Humans
  • Animals
  • Horses
  • 8-Hydroxy-2'-Deoxyguanosine
  • Neurodegenerative Diseases / veterinary
  • Case-Control Studies
  • NAD
  • Horse Diseases / diagnosis
  • Neuroaxonal Dystrophies / veterinary
  • Ataxia / veterinary

Grant Funding

  • 1-400666-xxxx-2000-5919 / Firestone/Tamworth/Raker-Tulleners Grant

Conflict of Interest Statement

Authors declare no conflict of interest.

References

This article includes 28 references
  1. Wong DM, Ghosh A, Fales‐Williams AJ, Haynes JS, Kanthasamy AG. Evidence of oxidative injury of the spinal cord in 2 horses with equine degenerative myeloencephalopathy. Vet Pathol. 2012;49(6):1049‐1053.
    pubmed: 22390882
  2. Edwards LA, Donnelly CA, Reed SM, et al. Serum and cerebrospinal fluid phosphorylated neurofilament heavy protein concentrations in equine neurodegenerative diseases. Equine Vet J. 2022;54(2):290‐298.
    pubmed: 33969539
  3. Mayhew IG, Brown CM, Stowe HD, et al. Equine degenerative myeloencephalopathy: a vitamin E deficiency that may be familial. J Vet Intern Med. 1987;1(1):45‐50.
    pubmed: 3506620
  4. Aleman M, Finno CJ, Higgins RJ, et al. Evaluation of epidemiological, clinical, and pathologic features of neuroaxonal dystrophy in quarter horses. J Am Vet Med Assoc. 2011;239(6):823‐833.
    pubmed: 21916766
  5. nJohnson AL. Equine degenerative myeloencephalopathy: an updated clinical perspective. ACVIM Forum Proceedings, 2019. available at vin.com/acvim/2019.
  6. Hales EN, Habib H, Facro G, et al. Increased α‐tocopherol metabolism in horses with equine neuroaxonal dystrophy. J Vet Intern Med. 2021;35(5):2473‐2485.
    pmc: PMC8478026pubmed: 34331715
  7. Sokol RJ, Guggenheim MA, Heubi JE, et al. Frequency and clinical progression of the vitamin E deficiency neurologic disorder in children with prolonged neonatal cholestasis. JAMA Pediatr. 1985;139(12):1211‐1215.
    pubmed: 4061425
  8. Lee P, Ulatowski LM. Vitamin E: mechanism of transport and regulation in the CNS. IUBMB Life. 2019;71(4):424‐429.
    pubmed: 30556640
  9. Dill SG, Correa MT, Erb HN, DeLahunta A, Kallfelz FA, Waldron C. Factors associated with the development of equine degenerative myeloencephalopathy. Am J Vet Res. 1990;51(8):1300‐1305.
    pubmed: 2386332
  10. Finno CJ, Estell KE, Winfield L, et al. Lipid peroxidation biomarkers for evaluating oxidative stress in equine neuroaxonal dystrophy. J Vet Intern Med. 2018;32(5):1740‐1747.
    pmc: PMC6189351pubmed: 30133798
  11. Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem. 1999;72:771‐776.
    pubmed: 9930752
  12. Bogdanov M, Brown RH Jr, Matson W, et al. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med. 2000;29(7):652‐658.
    pubmed: 11033417
  13. Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q‐10 and 8‐hydroxy‐2′‐deoxyguanosine in the CSF of patients with Alzheimer's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. J Neurol. 2010;257(3):399‐404.
    pubmed: 19784856
  14. Niedzwiedz A, Borowicz H, Januszewska L, Markiewicz‐Gorka I, Jaworski Z. Serum 8‐hydroxy‐2‐deoxyguanosine as a marker of DNA oxidative damage in horses with recurrent airway obstruction. Acta Vet Scand. 2016;58(1):38.
    pmc: PMC4895991pubmed: 27267076
  15. Migliore L, Fontana I, Colognato R, Coppede F, Siciliano G, Murri L. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging. 2005;26(5):587‐595.
    pubmed: 15708433
  16. Blythe LL, Hultgren BD, Craig AM, et al. Clinical, viral, and genetic evaluation of equine degenerative myeloencephalopathy in a family of appaloosas. JAVMA. 1991;198(6):1005‐1013.
    pubmed: 2032902
  17. Burns EN, Finno CJ. Equine degenerative myeloencephalopathy: prevalence, impact, and management. Vet Med (Auckl). 2018;9:63‐67.
    pmc: PMC6135079pubmed: 30234005
  18. Finno CJ, Famula T, Aleman M, Higgins RJ, Madigan JE, Bannasch DL. Pedigree analysis and exclusion of alpha‐tocopherol transfer protein (TTPA) as a candidate gene for neuroaxonal dystrophy in the American Quarter Horse. J Vet Intern Med. 2013;27(1):177‐185.
    pmc: PMC4557866pubmed: 23186252
  19. Beech J, Haskins M. Genetic studies of neuraxonal dystrophy in the Morgan. Am J Vet Res. 1987;48(1):109‐113.
    pubmed: 3826829
  20. Bedenice D, Johnson AL. Neurologic conditions in the sport horse. Anim Front. 2022;12(3):37‐44.
    pmc: PMC9197298pubmed: 35711509
  21. Donnelly CG, Finno CJ. Vitamin E depletion is associated with subclinical axonal degeneration in juvenile horses. Equine Vet J. 2023;55(5):884‐890.
    pmc: PMC10264549pubmed: 36516303
  22. Story MR, Haussler KK, Nout‐Lomas YS, et al. Equine cervical pain and dysfunction: pathology, diagnosis and treatment. Animals (Basel). 2021;11(2):422.
    pmc: PMC7915466pubmed: 33562089
  23. Woodie B, Johnson AL, Grant B. Cervical vertebral stenotic myelopathy. Vet Clin North Am Equine Pract. 2022;38(2):225‐248.
    pubmed: 35953144
  24. Mittelman NS, Stefanovski D, Johnson AL. Utility of C‐reactive protein and serum amyloid A in the diagnosis of equine protozoal myeloencephalitis. J Vet Intern Med. 2018;32(5):1726‐1730.
    pmc: PMC6189384pubmed: 30216559
  25. Reed SM, Howe DK, Morrow JK, et al. Accurate antemortem diagnosis of equine protozoal myeloencephalitis (EPM) based on detecting intrathecal antibodies against Sarcocystis neurona using the SnSAG2 and SnSAG4/3 ELISAs. J Vet Intern Med. 2013;27(5):1193‐1200.
    pubmed: 24033423
  26. Reed SM, Furr M, Howe DK, et al. Equine protozoal myeloencephalitis: an updated consensus statement with a focus on parasite biology, diagnosis, treatment, and prevention. J Vet Intern Med. 2016;30(2):491‐502.
    pmc: PMC4913613pubmed: 26857902
  27. Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta. 1987;163:319‐328.
    pubmed: 3581475
  28. Dubey JP, Lindsay DS, Saville WJA, Reed SM, Granstrom DE, Speer CA. A review of sarcocystic neurona and equine protozoal myeloencephalitis (EPM). Vet Parasitol. 2001;95:89‐131.
    pubmed: 11223193

Citations

This article has been cited 1 times.
  1. Șerban M, Toader C, Covache-Busuioc RA. The Redox Revolution in Brain Medicine: Targeting Oxidative Stress with AI, Multi-Omics and Mitochondrial Therapies for the Precision Eradication of Neurodegeneration.. Int J Mol Sci 2025 Aug 3;26(15).
    doi: 10.3390/ijms26157498pubmed: 40806624google scholar: lookup